ARTH:OTC-Arch Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.17

Change

-0.01 (-3.32)%

Market Cap

USD 0.03B

Volume

0.18M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-0.95 (-1.33%)

USD164.04B 29.07 2.82
CMXHF CSL Limited

-4.95 (-2.33%)

USD96.74B 36.41 25.41
SBHMY Sino Biopharmaceutical Limited

-0.46 (-2.00%)

USD22.68B 35.23 3.07
SBMFF Sino Biopharmaceutical Limited

N/A

USD22.19B 36.36 3.67
GNMSF Genmab A/S

-14.20 (-4.20%)

USD21.85B 94.33 3.17
UCBJY UCB SA

-2.02 (-3.95%)

USD19.23B 18.93 16.14
UCBJF UCB SA

-9.50 (-8.89%)

USD19.21B 19.79 16.14
PPTDF PeptiDream Inc

N/A

USD5.99B 260.99 1.82
ABCZF Abcam plc

-0.40 (-1.77%)

USD4.99B 56.77 131.20
GENSF Genus plc

N/A

USD4.75B 65.57 53.60

ETFs Containing ARTH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.74% 35% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.74% 34% F 49% F
Trailing 12 Months  
Capital Gain -23.18% 17% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.18% 17% F 14% F
Trailing 5 Years  
Capital Gain -9.14% 53% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.14% 53% F 32% F
Average Annual (5 Year Horizon)  
Capital Gain -16.64% 20% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.64% 19% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 41.65% 73% C 48% F
Risk Adjusted Return -39.96% 19% F 19% F
Market Capitalization 0.03B 56% F 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -6.71 58% F 75% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 503.93% 93% A 98% A+
Return on Assets -109.58% 34% F 10% F
Debt to Equity Ratio -9.25% 64% D 86% B
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.10 76% C 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector